App improves survival of advanced cancer patients by 5 months

Cara Livernois | | Health Exec | Precision Medicine

Ethan Basch, MD, has developed a web-based tool for cancer patients to report symptoms on a weekly basis. The Symptom Tracking And Reporting (STAR) tool aims to improve quality of life and reduce emergency room visits for patients with advanced cancers.

In studies on the app, researchers were able to increase the survival of 766 patients with advanced urologic, gynecologic, breast or lung cancer by an average of five months.

“This tool brings us closer to the country doctor model,” Basch said. “We’re in touch with our patients on a regular basis, he said. “As an oncologist, it makes me feel like my patients aren’t ‘out of sight and out of mind.’ When my patients are using this tool, I worry less that they’re going to experience something and I won’t know about it,” he said. “If patients are experiencing a problem, we can reach out.”

Read the full story below:

The Paradoxical Benefits Of A Web App For Cancer Patients

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup